Literature DB >> 27059324

Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Laura Ardighieri1, Luigi Mori2, Sara Conzadori3, Mattia Bugatti3, Marcella Falchetti3, Carla Maria Donzelli3, Antonella Ravaggi4, Franco E Odicino5, Fabio Facchetti3.   

Abstract

Pelvic carcinosarcomas (PCSs) are rare aggressive biphasic tumors that localize in the ovary, fallopian tube, or peritoneum and present frequently as bilateral disease. We undertook a morphological, p53 immunohistochemical and TP53 gene mutational analysis study in a single institution cohort of 16 PCSs in order to investigate the nature of bilateral tumors and to shed light on their origin and pathogenesis. Of the 16 patients, 10 presented with bilateral disease, 6 with a carcinosarcoma in both adnexa, and the remaining cases with a carcinosarcoma in one adnexum and a carcinoma in the opposite. The carcinoma component showed high-grade serous features in 13/16 of cases (81 %). In 10 patients (63 %), a serous tubal intraepithelial carcinoma (STIC) was found, in one case bilateral, making a total of 11 STICs. STIC was found only in cases with a carcinoma component with high-grade serous features. All 10 bilateral tumors and all 11 PCS-associated STICs showed a similar p53 immunostaining pattern. At mutation analysis of the TP53 gene, all five bilateral PCS contained an identical mutation in both localizations. Furthermore, a TP53 mutation was found in 8 of 10 STICs, with an identical mutation in the associated PCS. The finding of similar p53 immunostaining in all bilateral cases and identical TP53 mutations in most PCS-associated STIC provides evidence for a clonal relation between these neoplastic lesions, supporting a metastatic nature of bilateral PCS and suggesting that they have an extraovarian origin in a STIC.

Entities:  

Keywords:  Bilateral; Carcinosarcoma; STIC; TP53; p53

Mesh:

Year:  2016        PMID: 27059324     DOI: 10.1007/s00428-016-1933-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  38 in total

1.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

Review 2.  Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.

Authors:  Vera Loizzi; Gennaro Cormio; Anna Camporeale; Maddalena Falagario; Paola De Mitri; Doriana Scardigno; Giuseppe Putignano; Luigi E Selvaggi
Journal:  Oncology       Date:  2011-06-14       Impact factor: 2.935

3.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

4.  p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.

Authors:  M J Costa; J Vogelsan; L J Young
Journal:  Mod Pathol       Date:  1994-08       Impact factor: 7.842

5.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Authors:  Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

6.  Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature.

Authors:  Ma-Lee Ko; Cherng-Jye Jeng; Shih-Hung Huang; Jenta Shen; Chii-Ruey Tzeng; Su-Chee Chen
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

7.  Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).

Authors:  Jeffrey D Seidman
Journal:  Int J Gynecol Pathol       Date:  2015-03       Impact factor: 2.762

8.  The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.

Authors:  Gautier Chene; Veronique Ouellet; Kurosh Rahimi; Veronique Barres; Diane Provencher; Anne Marie Mes-Masson
Journal:  Int J Gynaecol Obstet       Date:  2015-04-11       Impact factor: 3.561

9.  Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study.

Authors:  Chien-Hsing Lu; I-Hui Chen; Yi-Jen Chen; Kung-Liahng Wang; Jian-Tai Timothy Qiu; Hao Lin; Wu-Chou Lin; Wen-Shiung Liou; Yu-Fang Huang; Yue-Shan Lin; Yi-Torng Tee; Yao-Ching Hung
Journal:  Int J Gynecol Cancer       Date:  2014-03       Impact factor: 3.437

10.  Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases.

Authors:  P A de Brito; S G Silverberg; J M Orenstein
Journal:  Hum Pathol       Date:  1993-02       Impact factor: 3.466

View more
  8 in total

1.  Bulky peritoneal carcinosarcoma with tiny high-grade serous carcinoma of the fallopian tube: a case report.

Authors:  Ayaka Nakashima; Yasuyo Maruyama; Haruya Saji; Tomoo Hirabuki; Hiroyuki Mitomi
Journal:  Int Cancer Conf J       Date:  2020-10-19

2.  High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.

Authors:  Yali Zhai; Rong Wu; Rork Kuick; Michael S Sessine; Stephanie Schulman; Megan Green; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2017-07-25       Impact factor: 7.996

3.  Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review.

Authors:  Shanshan Guo; Xiaoyun Zhang; Qianjue Tang; Mengyun Zhou; Dan Jiang; Erkai Yu
Journal:  Onco Targets Ther       Date:  2022-06-29       Impact factor: 4.345

Review 4.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

5.  Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.

Authors:  Rosie T Jiang; Anna Yemelyanova; Deyin Xing; Ravi K Anchoori; Jun Hamazaki; Shigeo Murata; Jeffrey D Seidman; Tian-Li Wang; Richard B S Roden
Journal:  J Ovarian Res       Date:  2017-08-07       Impact factor: 4.234

6.  Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?

Authors:  Nyamdelger Sukhbaatar; Anna Bachmayr-Heyda; Katharina Auer; Stefanie Aust; Simon Deycmar; Reinhard Horvat; Dietmar Pils
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-07-05

7.  Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.

Authors:  Graziela Zibetti Dal Molin; Carina Meira Abrahão; Robert L Coleman; Fernando Cotait Maluf
Journal:  Gynecol Oncol Res Pract       Date:  2018-08-18

8.  Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread.

Authors:  Joshua D Bernstock; Stuart Ostby; Brandon Fox; Houman Sotoudeh; Andrew Janssen; Yun Jee Kang; Jason Chen; Veeranjaneyulu Prattipati; Galal Elsayed; Gustavo Chagoya; Daisuke Yamashita; Gregory K Friedman; Burt Nabors; Warner K Huh; Mina Lobbous
Journal:  Clin Case Rep       Date:  2019-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.